Brooks Laboratories Ltd

Know More
NSEBSE

120.902.40 (2.03%)

10:44 AM,29th Feb 2024

120.55-0.30 (-0.25%)

10:49 AM,29th Feb 2024

BSE : 533543

NSE : BROOKS

Sector : Health care

ISIN Code : INE650L01011

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Feb 29 2024 | 10:49 AM IST

Market Cap (₹ Cr)

317

Turnover (₹ Cr)

0.02

Volume (Shares)

17852

Face Value

10

52-WK High

185.70

52-WK High Date

10 Jan 2024

52-WK Low

56.95

52-WK Low Date

25 May 2023

All Time High

185.70

All Time High Date

10 Jan 2024

All Time Low

10.29

All Time Low Date

02 Jan 2012

Brooks Laboratories Ltd

Brooks Laboratories Ltd is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi Himachal Pradesh and Vadodara Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam Cephalosporin & General Dry powder Injectables Ampoules and Liquid vials Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables 19 Tablets and 2 Dry Syrups which are marketed domestically.The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi they manufacture wide range of products under the formulation segment for various top notch companies of India.The company's major clients are companies like Zydus Cadila Aristo Pharmaceuticals Pvt Ltd FDC Ltd Nectar Lifesciences Ltd Sanat Products Ltd Hetero Healthcare Ltd Medley Pharmaceuticals Wockhardt Ltd Parental Drugs Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd Aurobindo Pharma Ltd DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.Brooks Laboratories Ltd was incorporated on January 23 2002. The company was initially promoted for manufacturing latest molecules in Injectables tablets and dry syrups for the domestic customers. In the year 2006 the company set up a facility for manufacturing Tablets Dry Syrup and Injectables which was supported by a research and development (R&D) centre at Baddi Himachal Pradesh. In May 2006 they started their operations and in June 3 2006 they commenced commercial production.In October 2006 the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007 they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd Australia. In April 2008 the company took over some of the assets of Brooks Pharmaceuticals a partnership firm of the promoters Atul Ranchal & Rajesh Mahajan.In April 2010 the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare HP. In July 2010 the company received an ISO 9001:2008 Certificate from UKAS Quality Management URS & IAF.In August 2011 Brooks Laboratories raised Rs. 63 crore from the public through IPO. The shares of the company got listed on the stock exchanges with effect from 5 September 2011.During the financial year ended 31 March 2014 the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015 the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016 the company operated the Baddi plant at 92% capacity.On 7 March 2017 Brooks Laboratories' world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit the company decided to upgrade the Baddi facility in steps. As a first step the company upgraded one injectable manufacturing line which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017 whereby production in injectable line was affected upgradation was completed and production started from September onwards in Baddi facility. During the year ended 31 March 2018 the company operated the Baddi plant at 90% capacity except for 3 months from June to August due to upgradation of injectable facility in Baddi.The company commenced production in August 2017 in new renovated building at Baddi plant with almost double the capacity of previous line.

Brooks Laboratories Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

317

EPS - TTM (₹) [S]

0.19

P/E Ratio (X) [S]

4.62

Face Value (₹) 10
Latest Dividend (%)-
Latest Dividend Date -
Dividend Yield (%) -
Book Value Share (₹) [S]26.17
P/B Ratio (₹) [S]4.62
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Quant Business Cycle Fund - Regular (G) 7.83 528937 0.75
Quant Business Cycle Fund - Regular (IDCW) 7.83 528937 0.75
Quant Business Cycle Fund - Direct (G) 7.83 528937 0.75
Quant Business Cycle Fund - Direct (IDCW) 7.83 528937 0.75
Quant Healthcare Fund - Regular (G) 7.17 484054 3.03
Quant Healthcare Fund - Regular (IDCW) 7.17 484054 3.03
Quant Healthcare Fund - Direct (G) 7.17 484054 3.03
Quant Healthcare Fund - Direct (IDCW) 7.17 484054 3.03

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

118.30

121.35

Week Low/High

116.80

130.00

Month Low/High

116.80

156.00

Year Low/High

56.95

186.00

All time Low/High

10.32

186.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-1.23%-1.27%-1.33-1.39%
1 Month-19.99%-19.99%0.340.79%
3 Month-4.80%-6.28%7.909.02%
6 Month31.41%28.62%10.9213.27%
1 Year27.71%27.68%22.4226.61%
3 Year106.38%107.95%47.0150.79%

Company Info

Company Information

Chairman : Atul Ranchal

Managing Director : Rajesh Mahajan

Director & Chief Executive Off : Durga Sankar Maity

Independent Director : Rajnish Kumar Bedi

Independent Director : Deepak Mahajan

Independent Director : Sonia Gupta

Company Secretary : Jyoti Sancheti

Registered Office: Village Kishanpura, Nilagarh Road Baddi,Solan,Himachal Pradesh-174101 Ph: 91-1795-654001/02/03

Email:investors@brookslabs.net

URL:http://www.brookslabs.net